Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer

  • Technology appraisal guidance
  • TA1122
  • Published: 
Download guidance (PDF)

Update information

Minor changes since publication

April 2026: We added details of the subcutaneous form of amivantamab to section 2.

ISBN: 978-1-4731-7776-5